Edluar the second US launch for Meda in two months
This article was originally published in Scrip
Meda Pharmaceuticals has launched its second new product in the US in two months – its sublingual formulation of zolpidem tartrate (Edluar), 5mg and 10mg tablets. Last month, it launched a higher dose formulation (0.15%) of its nasal antihistamine spray, Astepro (azelastine).
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An interim analysis of the Phase III KEYNOTE-355 study in triple-negative breast cancer patients reports that first-line pembrolizumab combined with chemotherapy has met the PFS primary endpoint, but Merck & Co is still a long way behind Roche’s Tecentriq in the additional indication.
The cost-effectiveness of combination therapies for untreated advanced renal cell carcinoma therapies comes under the spotlight as England's HTA body rejects an immunotherapy/kinase inhibitor combination in draft guidance.